Visit Contract Pharma
at Booth 1815

Grand River Expands Manufacturing Capacity


New Bausch+Ströbel filler can fill 200 vials per minute and more than triples Grand River's manufacturing capacity

Grand River Aseptic Manufacturing, a parenteral contract development and manufacturing organization (CDMO), has made its second major equipment purchase this year: a state-of-the-art Bausch+Ströbel fully integrated high-speed filling line with SKAN isolator.

The Bausch+Ströbel filler can fill 200 vials per minute and will more than triple Grand River's manufacturing capacity, maximizing flexibility in manufacturing solutions, increasing process efficiency and ensuring the highest level of sterility. The fully integrated fill line includes a vial washer, depyrogenation tunnel and filling machine and will fill vials ranging from 2mL to 50mL with 100% weight checks.

"GRAM continues to build our flexibility in the highly competitive CDMO market," said Nick Bykerk, vice president of business development and finance, Grand River. "Simultaneously, we are reinvesting in the development of our clinical-scale manufacturing. The combination of specialized clinical and commercial production with our analytical and development services offers a powerful solution to better meet the evolving needs of our clients."

The company is scheduling new projects starting in summer 2019. Tom Ross, president and chief executive officer of Grand River, said, "The fully integrated filling line is a significant capital investment capable of executing clients' complex parenteral manufacturing processes with the utmost precision. We look forward to serving our customers through additional investments in our facilities and finishing areas, including inspection, labeling and packaging."

Grand River's aggressive expansion plans also include the recent completion of a major land purchase agreement and the purchase of a new syringe filler.

"Grand River has always centered around quality and service, which has led to explosive growth," said Mr. Ross. "With Arlington Capital joining our company last November, we have the financial resources to invest in our customers through a planned expansion, new state-of-art injectable fill/finish equipment and additional highly trained staff."

To learn more about Grand River's parenteral capabilities, visit